Experience

Unlearn.AI

• United States
• Research Services
• 1 - 100 Employee

• Research Biostatistician

  • Dec 2021 - Present

  Responsible for developing statistical methodology for PROCOVA and PROCOVA+ in new endpoints, diseases, and trial designs; asymptotically and through simulation. Active in clinical trial design and regulatory submissions. Responsible for developing statistical methodology for PROCOVA and PROCOVA+ in new endpoints, diseases, and trial designs; asymptotically and through simulation. Active in clinical trial design and regulatory submissions.



Hospital for Special Surgery

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Biostatistician and Data Analyst

  • Aug 2021 - Nov 2021

  Primary statistician and data analyst for MRI technology research in joint injuries/conditions. Primary statistician and data analyst for MRI technology research in joint injuries/conditions.



The Institute of Cancer Research

• United Kingdom
• Research
• 700 & Above Employee

• Postgraduate Student

  • Oct 2020 - Jul 2021

  [Research position.] Conducted independent research on platform trial design. Published a rapid review of platform trials in COVID-19 (2021). [Research position.] Conducted independent research on platform trial design. Published a rapid review of platform trials in COVID-19 (2021).



Columbia University Irving Medical Center

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Assistant Statistician

  • May 2019 - May 2020

  Data analysis and statistical analysis plan for ROKHyT pilot study for hypertension Data analysis and statistical analysis plan for ROKHyT pilot study for hypertension



Columbia University Mailman School of Public Health

• United States
• Higher Education
• 500 - 600 Employee

• Research Assistant

  • Oct 2018 - May 2020

  (Master's Capstone) Phase I clinical trials that assess safety typically use the event of a dose-limiting toxicity as an endpoint. I extended a novel two-stage adaptive dose-finding trial design ("iAdapt") to quasi-continuous toxicity endpoint and published the corresponding R package iAdapt on CRAN (2019). (Master's Capstone) Phase I clinical trials that assess safety typically use the event of a dose-limiting toxicity as an endpoint. I extended a novel two-stage adaptive dose-finding trial design ("iAdapt") to quasi-continuous toxicity endpoint and published the corresponding R package iAdapt on CRAN (2019).



The Data Science Institute at Columbia University

• United States
• Higher Education
• 1 - 100 Employee

• Data Science Institute Scholar

  • Jun 2019 - Sep 2019

  Natural Language Processing and machine learning in R for clinical notes to predict future patient events. Natural Language Processing and machine learning in R for clinical notes to predict future patient events.



Dana-Farber Cancer Institute

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Research Assistant

  • Oct 2016 - Jul 2018

  An original member of the Program in Regulatory Science at Dana-Farber Cancer Institute. First author on the group's first publication in 2018. Focus on trial data, meta-analysis, and methodology in phase II clinical trials for glioblastoma. An original member of the Program in Regulatory Science at Dana-Farber Cancer Institute. First author on the group's first publication in 2018. Focus on trial data, meta-analysis, and methodology in phase II clinical trials for glioblastoma.



Boston University

• United States
• Higher Education
• 700 & Above Employee

• Student - Summer Institute for Training in Biostatistics

  • Jun 2015 - Jul 2015